Cargando…
Lungenbeteiligung bei Tumorkrankheiten
The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782564/ http://dx.doi.org/10.1007/s11654-020-00280-x |
_version_ | 1783631932347645952 |
---|---|
author | Reinmuth, N. Mavi, S.-C. |
author_facet | Reinmuth, N. Mavi, S.-C. |
author_sort | Reinmuth, N. |
collection | PubMed |
description | The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other cancer entities. Various treatment modalities, such as tyrosine kinase inhibitors, checkpoint inhibitors, chimeric antigen receptor cell therapy, and radiotherapy approaches can cause pulmonary side effects. Finally, many patients suffer from pulmonary comorbidities which may mutually impact the clinical course and prognosis of the cancer disease. As examples, various aspects, such as pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are discussed. |
format | Online Article Text |
id | pubmed-7782564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-77825642021-01-05 Lungenbeteiligung bei Tumorkrankheiten Reinmuth, N. Mavi, S.-C. best practice onkologie CME Topic The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other cancer entities. Various treatment modalities, such as tyrosine kinase inhibitors, checkpoint inhibitors, chimeric antigen receptor cell therapy, and radiotherapy approaches can cause pulmonary side effects. Finally, many patients suffer from pulmonary comorbidities which may mutually impact the clinical course and prognosis of the cancer disease. As examples, various aspects, such as pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are discussed. Springer Medizin 2021-01-05 2021 /pmc/articles/PMC7782564/ http://dx.doi.org/10.1007/s11654-020-00280-x Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | CME Topic Reinmuth, N. Mavi, S.-C. Lungenbeteiligung bei Tumorkrankheiten |
title | Lungenbeteiligung bei Tumorkrankheiten |
title_full | Lungenbeteiligung bei Tumorkrankheiten |
title_fullStr | Lungenbeteiligung bei Tumorkrankheiten |
title_full_unstemmed | Lungenbeteiligung bei Tumorkrankheiten |
title_short | Lungenbeteiligung bei Tumorkrankheiten |
title_sort | lungenbeteiligung bei tumorkrankheiten |
topic | CME Topic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782564/ http://dx.doi.org/10.1007/s11654-020-00280-x |
work_keys_str_mv | AT reinmuthn lungenbeteiligungbeitumorkrankheiten AT mavisc lungenbeteiligungbeitumorkrankheiten |